Dena A. Jerjees
Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer
Jerjees, Dena A.; Alabdullah, M.; Green, Andrew R.; Alshareeda, Alaa; Macmillan, R. D.; Ellis, Ian O.; Rakha, Emad A.
Authors
M. Alabdullah
ANDREW GREEN andrew.green@nottingham.ac.uk
Associate Professor
Alaa Alshareeda
R. D. Macmillan
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Abstract
The definition of Luminal-B subclass of breast cancer (BC) varies in literature. In this study, we have compared the proliferation status; assessed using KI67 labeling index (KI67-LI), and HER2-expression in estrogen receptor positive (ER+) BC to assess their impact on the biological and clinical characteristics of luminal-BC. 1547 (73.8 %) well-characterized clinically annotated stage I–III ER + BC were assessed for expression of KI67, HER2 (ASCO guidelines), and a large panel of relevant biomarkers (no = 37). 46.3 % of the cases show high KI67-LI (>13 %) and 8.4 % show HER2+ and both markers are positively associated with younger age, higher tumor grade and poorer outcome. High KI67-LI and HER2+ are associated with upregulation of ER-coactivators and proliferation-related markers and with downregulation of good prognostic markers. High KI67-LI is associated with larger size, advanced stage, and lymphovascular invasion (LVI) and with downregulation of luminal-enriched and DNA-damage repair markers. In contrast, HER2+ is associated with upregulation of ER-regulated proteins and E-cadherin. When analysis is restricted to high KI67-LI subgroup, HER2+ shows an association with upregulation of differentiation-associated proteins and E-cadherin. Conversely, within HER2+ class, high KI67-LI maintains its association with downregulation of differentiation-associated/luminal-enriched proteins. Outcome analyses indicate that both markers are independently associated with shorter survival but HER2+ is associated with a worse outcome. Although both are associated with high proliferation and poor prognosis within ER + BC, HER2+ is less frequent than high KI67-LI. Unlike KI67, HER2 seems to independently drive the aggressive behavior of ER+ tumors without downregulation of luminal proteins.
Citation
Jerjees, D. A., Alabdullah, M., Green, A. R., Alshareeda, A., Macmillan, R. D., Ellis, I. O., & Rakha, E. A. (2014). Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast Cancer Research and Treatment, 145(2), 317-330. doi:10.1007/s10549-014-2941-7
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 26, 2014 |
Online Publication Date | Apr 18, 2014 |
Publication Date | 2014-06 |
Deposit Date | Oct 17, 2018 |
Journal | Breast Cancer Research and Treatment |
Print ISSN | 0167-6806 |
Electronic ISSN | 1573-7217 |
Publisher | BMC |
Peer Reviewed | Peer Reviewed |
Volume | 145 |
Issue | 2 |
Pages | 317-330 |
DOI | https://doi.org/10.1007/s10549-014-2941-7 |
Public URL | https://nottingham-repository.worktribe.com/output/1172407 |
Publisher URL | https://link.springer.com/article/10.1007%2Fs10549-014-2941-7 |
You might also like
Adenomyoepithelioma of the breast: A proposal for classification
(2021)
Journal Article